Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker EXEL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lu… NCT07845786 · Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel | EXEL Exelixis | Phase 2 | Recruiting was not yet recruiting | 60 | Jun 15, 2028 | Registry ↗ |
| Nov 12, 2026 | Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants… NCT07750158 · Colorectal Cancer Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa | EXEL Exelixis | Phase 3 | Recruiting | 600 | Apr 5, 2030 | Registry ↗ |
| Nov 6, 2026 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tum… NCT05932862 · Advanced Solid Tumor XL309, Olaparib | EXEL Exelixis | Phase 1 | Active, not recruiting was recruiting | 429 | Apr 30, 2027 | Registry ↗ |
| Oct 30, 2026 | Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine… NCT06943755 · Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Ne… Zanzalintinib, Everolimus | EXEL Exelixis | Phase 2/3 | Recruiting | 440 | Jun 30, 2029 | Registry ↗ |
| Oct 30, 2026 | Study of XB010 in Subjects With Solid Tumors NCT06545331 · Locally Advanced or Metastatic Solid Tumors, Esophageal Squ… XB010, Pembrolizumab | EXEL Exelixis | Phase 1 | Recruiting | 396 | Nov 23, 2026 | Registry ↗ |
| Oct 28, 2026 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study NCT07620574 · Cancer, Renal Cell Carcinoma (RCC) Cabozantinib, Zanzalintinib | EXEL Exelixis | Phase 3 | Enrolling by invitation | 5,000 | May 31, 2030 | Registry ↗ |
| Oct 28, 2026 | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma NCT07428616 · Meningioma Zanzalintinib | EXEL Exelixis | Phase 2 | Recruiting | 100 | Feb 29, 2028 | Registry ↗ |
| Oct 20, 2026 | Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untr… NCT03937219 · Renal Cell Carcinoma Cabozantinib, Nivolumab | EXEL Exelixis | Phase 3 | Active, not recruiting | 855 | Jan 31, 2022 | Registry ↗ |
| Oct 20, 2026 | A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiate… NCT03690388 · Differentiated Thyroid Cancer Cabozantinib, Placebo | EXEL Exelixis | Phase 3 | Active, not recruiting | 187 | Aug 19, 2020 | Registry ↗ |
| Oct 20, 2026 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid… NCT01896479 · Medullary Thyroid Cancer Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg | EXEL Exelixis | Phase 4 | Active, not recruiting | 247 | Jul 15, 2020 | Registry ↗ |
| Oct 1, 2026 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Sol… NCT05176483 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant… Zanzalintinib, Nivolumab | EXEL Exelixis | Phase 1 | Recruiting | 1,394 | Jan 31, 2027 | Registry ↗ |
| Oct 1, 2026 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced o… NCT03170960 · Urothelial Carcinoma, Renal Cell Carcinoma cabozantinib, atezolizumab | EXEL Exelixis | Phase 1 | Active, not recruiting | 914 | Feb 21, 2023 | Registry ↗ |
| Aug 19, 2026 | Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors NCT07773454 · Cancer, Pediatric Cancer Zanzalintinib | EXEL Exelixis | Phase 1 | Not yet recruiting | 18 | Jul 31, 2028 | Registry ↗ |
| Jul 29, 2026 | Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Rena… NCT05678673 · Non-Clear Cell Renal Cell Carcinoma XL092, Nivolumab | EXEL Exelixis | Phase 3 | Active, not recruiting | 317 | Dec 15, 2026 | Registry ↗ |
| Jul 17, 2026 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer NCT05425940 · Colorectal Cancer XL092, Atezolizumab | EXEL Exelixis | Phase 3 | Active, not recruiting | 901 | Jun 16, 2026 | Registry ↗ |
| Jun 24, 2026 | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advance… NCT06952010 · Solid Tumor, Advanced Solid Tumor XB628, Zanzalintinib | EXEL Exelixis | Phase 1 | Recruiting | 303 | May 31, 2027 | Registry ↗ |
| Feb 25, 2026 | Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or… NCT01068782 · Astrocytic Tumors Cabozantinib | EXEL Exelixis | Phase 2 | Terminated | 19 | May 2011 | Registry ↗ |
| Feb 17, 2026 | A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors NCT07123103 · Solid Tumors XB371 | EXEL Exelixis | Phase 1 | Recruiting | 150 | Nov 2027 | Registry ↗ |
| Jan 13, 2026 | A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Canc… NCT00596648 · Carcinoma, Non-Small-Cell Lung XL184, erlotinib | EXEL Exelixis | Phase 1/2 | Completed | 92 | Aug 2, 2012 | Registry ↗ |
| Jan 8, 2026 | Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC NCT01995058 · Prostate Cancer, Castration Resistant Prostate Cancer cabozantinib, abiraterone | EXEL Exelixis | Phase 2 | Terminated | 54 | Nov 2014 | Registry ↗ |
| Dec 18, 2025 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC NCT04446117 · Metastatic Prostate Cancer, Prostate Adenocarcinoma Cabozantinib, Atezolizumab | EXEL Exelixis | Phase 3 | Active, not recruiting | 575 | Apr 19, 2024 | Registry ↗ |
| Dec 11, 2025 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanc… NCT03755791 · Hepatocellular Carcinoma Cabozantinib, Cabozantinib | EXEL Exelixis | Phase 3 | Active, not recruiting | 837 | Nov 30, 2021 | Registry ↗ |
| Aug 17, 2025 | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Rec… NCT06082167 · Head and Neck Squamous Cell Carcinoma Zanzalintinib, Zanzalintinib-matched Placebo | EXEL Exelixis | Phase 2/3 | Active, not recruiting | 600 | Aug 2028 | Registry ↗ |
| Jun 25, 2025 | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced… NCT06630247 · Solid Cancers, Solid Tumor Cancer XL495, ADC cytotoxic agents | EXEL Exelixis | Phase 1 | Terminated | 9 | May 7, 2025 | Registry ↗ |
| Jun 22, 2025 | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment… NCT06962332 · Hepatic Impairment, Moderate Hepatic Impairment Zanzalintinib | EXEL Exelixis | Phase 1 | Recruiting | 20 | Dec 2025 | Registry ↗ |
| Jun 12, 2025 | Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With A… NCT06191796 · Advanced Clear Cell Renal Cell Carcinoma or Other Advanced… zanzalintinib, AB521 | EXEL Exelixis | Phase 1 | Terminated | 25 | May 12, 2025 | Registry ↗ |
| Apr 4, 2025 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) NCT04925284 · Non Small Cell Lung Cancer, Cervical Cancer XB002, Nivolumab | EXEL Exelixis | Phase 1 | Completed | 269 | Mar 10, 2025 | Registry ↗ |
| Nov 19, 2024 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors NCT03845166 · Neoplasm Malignant, Renal Cell Carcinoma XL092, Atezolizumab | EXEL Exelixis | Phase 1 | Active, not recruiting | 325 | Aug 31, 2026 | Registry ↗ |
| May 14, 2024 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) NCT04726332 · Neoplasm Malignant, Epithelial Ovarian Cancer XL102, Fulvestrant | EXEL Exelixis | Phase 1 | Terminated | 52 | May 2, 2024 | Registry ↗ |
| Apr 25, 2024 | Study of Cabozantinib (XL184) in Adults With Advanced Malignancies NCT00940225 · Solid Tumors, Cancer Cabozantinib, Placebo | EXEL Exelixis | Phase 2 | Completed | 730 | May 2013 | Registry ↗ |
| Feb 5, 2024 | Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme NCT00704288 · Glioblastoma Multiforme XL184 | EXEL Exelixis | Phase 2 | Completed | 222 | Jun 2012 | Registry ↗ |
| Jul 11, 2023 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma NCT05144347 · Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type Diffuse… XL114 | EXEL Exelixis | Phase 1 | Terminated | 2 | Nov 1, 2022 | Registry ↗ |
| May 6, 2021 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Receive… NCT01908426 · Hepatocellular Carcinoma Cabozantinib tablets, Placebo tablets | EXEL Exelixis | Phase 3 | Completed | 707 | Oct 16, 2017 | Registry ↗ |
| Apr 27, 2021 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma NCT01865747 · Renal Cell Carcinoma Cabozantinib tablets, Everolimus (Afinitor) tablets | EXEL Exelixis | Phase 3 | Completed | 658 | May 22, 2015 | Registry ↗ |
| Apr 20, 2021 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer NCT00704730 · Thyroid Cancer XL184, Placebo | EXEL Exelixis | Phase 3 | Completed | 330 | Oct 2011 | Registry ↗ |
| May 23, 2018 | Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Sy… NCT01522443 · Prostate Cancer, Castration Resistant Prostate Cancer cabozantinib, mitoxantrone | EXEL Exelixis | Phase 3 | Terminated | 119 | Oct 2014 | Registry ↗ |
| Mar 14, 2018 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostat… NCT01605227 · Prostate Cancer, Castration Resistant Prostate Cancer cabozantinib, prednisone | EXEL Exelixis | Phase 3 | Completed | 1,028 | Sep 2014 | Registry ↗ |
| Aug 21, 2015 | Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors NCT00796484 · Cancer XL888 | EXEL Exelixis | Phase 1 | Terminated | 33 | Nov 2010 | Registry ↗ |
| Aug 21, 2015 | A Phase 1 Study of XL019 in Adults With Polycythemia Vera NCT00595829 · Polycythemia Vera XL019 | EXEL Exelixis | Phase 1 | Terminated | 3 | Feb 2009 | Registry ↗ |
| Aug 21, 2015 | Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies NCT00526838 · Cancer, Lymphoma XL228 | EXEL Exelixis | Phase 1 | Terminated | 84 | Dec 2010 | Registry ↗ |
| Aug 21, 2015 | A Study of XL844 Administered as a Single Agent and in Combination With Gemcitabine in Adults With… NCT00475917 · Cancer, Lymphoma XL844, Gemcitabine | EXEL Exelixis | Phase 1 | Terminated | 28 | Dec 2008 | Registry ↗ |
| Aug 21, 2015 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute… NCT00464113 · Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, P… XL228 | EXEL Exelixis | Phase 1 | Terminated | 49 | Dec 2010 | Registry ↗ |
| Aug 20, 2015 | Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer NCT01553656 · Solid Tumors, Cancer cabozantinib capsules, cabozantinib tablets | EXEL Exelixis | Phase 1 | Completed | 85 | May 2015 | Registry ↗ |
| Aug 20, 2015 | Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors NCT00704392 · Cancer, Non-small-cell Lung Cancer XL647, XL147 | EXEL Exelixis | Phase 1 | Withdrawn | 0 | Dec 2009 | Registry ↗ |
44 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances